Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20010094 | 0.95 | ADORA2A (0.54) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL20010222 | 0.94 | ADORA2A (0.48) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL20009824 | 0.88 | DNMT1 (0.51) | ADORA2AADORA3ADORA2B | |
| SCHEMBL18852323 | 0.81 | ADORA3 (0.57) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL14928896 | 0.81 | ADORA3 (0.57) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL15868480 | 0.81 | ADORA3 (0.57) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL14946114 | 0.81 | ADORA3 (0.57) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL20010003 | 0.80 | ADORA2B (0.47) | ADORA2AADORA3ADORA1ADORA2BHSP90B1 | |
| SCHEMBL27715184 | 0.77 | ADORA3 (0.76) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2463066 | 0.77 | ADORA3 (0.64) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | ADORA2A 3329/4885ADORA3 3596/4885ADORA1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.